Department of Anesthesiology, Institute for Cardiovascular Research, VU University Medical Center, Amsterdam, The Netherlands.
J Cardiothorac Vasc Anesth. 2010 Jun;24(3):422-6. doi: 10.1053/j.jvca.2009.10.018. Epub 2010 Jan 6.
Dilutional coagulopathy as a consequence of cardiopulmonary bypass (CPB) system priming may also be affected by the composition of the priming solution. The direct effects of distinct priming solutions on fibrinogen, one of the foremost limiting factors during dilutional coagulopathy, have been minimally evaluated. Therefore, the authors investigated whether hemodilution with different priming solutions distinctly affects the fibrinogen-mediated step in whole blood clot formation.
Prospective observational laboratory study.
University hospital laboratory.
Eight male healthy volunteers.
Blood samples diluted with gelatin-, albumin-, or hydroxyethyl starch (HES)-based priming solutions were ex-vivo evaluated for clot formation by rotational thromboelastometry.
The intrinsic pathway (INTEM) coagulation time increased from 186 +/- 19 seconds to 205 +/- 16, 220 +/- 17, and 223 +/- 18 seconds after dilution with gelatin-, albumin-, or HES-containing prime solutions (all p < 0.05 v baseline). The extrinsic pathway (EXTEM) coagulation time was only minimally affected by hemodilution. Moreover, all 3 priming solutions significantly reduced the INTEM and EXTEM maximum clot firmness. The HES-containing priming solution induced the largest decrease in the maximum clot firmness attributed to fibrinogen, from 13 +/- 1 mm (baseline) to 6 +/- 1 mm (p < 0.01 v baseline).
All studied priming solutions prolonged coagulation time and decreased clot formation, but the fibrinogen-limiting effect was the most profound for the HES-containing priming solution. These results suggest that the composition of priming solutions may distinctly affect blood clot formation, in particular with respect to the fibrinogen component in hemostasis.
体外循环(CPB)系统预充可能导致稀释性凝血障碍,预充液的成分也可能对此产生影响。不同预充液对纤维蛋白原的直接作用,作为稀释性凝血障碍的主要限制因素之一,尚未得到充分评估。因此,作者研究了不同预充液对全血凝血块形成中纤维蛋白原介导步骤的影响。
前瞻性观察性实验室研究。
大学医院实验室。
8 名男性健康志愿者。
用明胶、白蛋白或羟乙基淀粉(HES)基预充液稀释血液样本,通过旋转血栓弹性测定法对凝血块形成进行体外评估。
内在途径(INTEM)凝血时间从 186 ± 19 秒增加到 205 ± 16、220 ± 17 和 223 ± 18 秒,在使用含有明胶、白蛋白或 HES 的预充液稀释后(均 p < 0.05 与基线相比)。外源性途径(EXTEM)凝血时间仅受轻微影响。此外,所有 3 种预充液均显著降低 INTEM 和 EXTEM 最大血凝块硬度。含有 HES 的预充液引起的纤维蛋白原最大血凝块硬度降低最大,从 13 ± 1 毫米(基线)降至 6 ± 1 毫米(p < 0.01 与基线相比)。
所有研究的预充液均延长凝血时间并减少凝血块形成,但含有 HES 的预充液对纤维蛋白原的限制作用最为明显。这些结果表明,预充液的成分可能会明显影响血凝块形成,特别是对止血过程中的纤维蛋白原成分。